Beautiful Virgin Islands

Friday, May 15, 2026

WHO suspends Sputnik V approval process over 'manufacturing' concerns

WHO suspends Sputnik V approval process over 'manufacturing' concerns

A regional WHO official said one manufacturing plant for the vaccine had failed to meet the necessary standards.

The World Health Organization (WHO) has suspended the approval process for Russia's Sputnik V COVID vaccine.

A regional WHO official said the manufacturing process of the jab had not met the necessary standards.

Russia first applied for approval from the WHO for their vaccine in February but has not yet received an Emergency Use Listing (EUL).

The WHO says they have delayed approving the jab until a new inspection can be carried out at one of the plants where Sputnik V was manufactured.

Research published in The Lancet medical journal shows that the vaccine has 91.6 per cent efficacy against the coronavirus.

On its official Twitter account, Sputnik also claimed on Wednesday that the jab demonstrated 97.2 per cent efficacy during the vaccination campaign in Belarus.

But both the WHO and European Medicines Agency (EMA) have said that they were still waiting for complete data from the vaccine's manufacturers.

Speaking at a press briefing for the Pan American Health Organization, a regional branch of the WHO, Assistant Director Jarbas Barbosa said Russia’s bid for emergency authorisation had been put on hold.

"While inspecting one of the plants where the vaccine is manufactured, they found that this plant was not in agreement with the new best practices of manufacturing," he said on Wednesday.

"The producer [of the vaccine] needs to take this into account and make the necessary changes and be ready for a new inspection."

"The WHO is waiting for the manufacturer to send news that the plant is up to standard," he added.

Previous concerns at Sputnik vaccine


The WHO had previously raised concerns about possible cross-contamination and insufficient during an inspection at Sputnik V manufacturing factory in Ufa.

In June, the company managing the plant -- Pharmstandard -- said in a statement that the WHO interim inspection "did not identify any critical issues".

"We invite WHO for another inspection. We remain fully transparent and will continue with the WHO pre-qualification process."

On Wednesday, Barbosa confirmed that Sputnik V must wait for approval until the new inspection can be carried out.

"Any vaccine manufacturer who wants to be approved by WHO has to submit all information about the quality and manufacturing process," Barbosa said.

"They need to prove that sites, where the vaccines are manufactured, are in agreement with best practices".

Gaining approval from the WHO would be a huge success for Russia, and could also facilitate the travel of millions of vaccinated Russian citizens.

Newsletter

Related Articles

Beautiful Virgin Islands
0:00
0:00
Close
The Great Western Exit: Why Best Citizens Are Fleeing the Rich World [PODCAST]
The New Robber Barons of Intelligence: Are AI Bosses More Powerful Than Rockefeller?
The End of the Old Order [Podcast]
Britain’s Democracy Is Now a Costume
The AI Gold Rush Is Coming for America’s Last Open Spaces [Podcast]
The Pentagon’s AI Squeeze: Eight Tech Giants Get In, Anthropic Gets Shut Out [Podcast]
The War Map: Professor Jiang’s Dark Theory of Iran, Trump, China, Russia, Israel, and the Coming Global Shock [Podcast]
Labour Is No Longer a National Party [Podcast]
AI Isn’t Stealing Your Job. It’s Dismantling It Piece by Piece.
Lawyers vs Engineers: Why China Builds While America Litigates [Podcast]
Churchill’s Glass: The Drunk, the Doctor, and the Myth Britain Refuses to Sober Up From
Apple issues an unusual warning: this is how your iPhone can be hacked without you doing anything
The Met Gala Meets the Age of Billionaire Backlash
Russian Oligarch’s Superyacht Crosses Hormuz via Iran-Controlled Route
Gunfire Disrupts White House Correspondents’ Dinner as Trump Is Evacuated
A Leak, a King, and a Fracturing Alliance
Inside the Gates Foundation Turmoil: Layoffs, Scrutiny, and the Cost of Reputational Risk
UK Biobank Breach Exposes Health Data of 500,000, Listed for Sale on Chinese Platform
KPMG Cuts Around 10% of US Audit Partners After Failed Exit Push
French Police Probe Suspected Weather-Data Tampering After Unusual Polymarket Bets on Paris Temperatures
News Roundup
Microsoft lost 2.5 millions users (French government) to Linux
Privacy Problems in Microsoft Windows OS
News roundup
Péter András Magyar and the Strategic Reset of Hungary
Hungary After the Landslide — A Strategic Reset in Europe
×